Sense and nonsense in sensors.
Continuous subcutaneous glucose monitoring (CGM) is a developing technology in the treatment of diabetes mellitus. The first randomised controlled trials on its efficacy have been performed. In several studies, CGM lowered HbA1c in adult patients with suboptimally controlled type 1 diabetes mellitus, when selecting compliant patients who tolerate the device. However, as a preventive tool for hypoglycaemia, CGM has not fulfilled the great expectations. Increasing reimbursement of CGM is expected in the near future, awaiting studies on cost-effectiveness.
Department of Internal Medicine, Academic Medical Centre, Amsterdam, the Netherlands.
J
J
Hermanides
J H
JH
DeVries
D000328:Adult; D001786:Blood Glucose / Q000032:analysis*; D002648:Child; D017281:Cost of Illness; D003922:Diabetes Mellitus, Type 1 / Q000097:blood*; D006442:Glycated Hemoglobin / Q000032:analysis*; D006801:Humans; D007003:Hypoglycemia / Q000453:epidemiology / Q000517:prevention & control; D018670:Monitoring, Ambulatory / Q000191:economics / Q000379:methods; D016032:Randomized Controlled Trials as Topic
D001786:Blood Glucose; D006442:Glycated Hemoglobin